Mechanisms of organ dysfunction and recovery in the Acetaminophen and Ascorbate Trial in Sepsis
对乙酰氨基酚和抗坏血酸脓毒症试验中器官功能障碍和恢复的机制
基本信息
- 批准号:10644023
- 负责人:
- 金额:$ 42.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-15 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AcetaminophenAcuteAcute Renal Failure with Renal Papillary NecrosisAcute Respiratory Distress SyndromeAffectAlveolarAngiopoietin-2AntibioticsAscorbic AcidBicarbonatesBiologicalBiological MarkersBlood capillariesCOVID-19Cardiovascular systemCellsCessation of lifeClassificationClinicalClinical TrialsDataDistalDouble-Blind MethodEndotheliumEpitheliumF2-IsoprostanesFunctional disorderFundingFutureHealth ExpendituresHemeproteinsHemodialysisHemoglobinHemoglobin concentration resultHeterogeneityHumanIL18 geneIL8 geneIn VitroIncidenceInfectionInflammationInflammatoryInjuryInjury to KidneyInterleukin-1 betaInterleukin-10Interleukin-6IntravenousLCN2 geneLifeLipid PeroxidationLiquid substanceLungMeasuresMechanical VentilatorsMechanical ventilationMethodsModelingMorbidity - disease rateNational Heart, Lung, and Blood InstituteOrganOutcomeOxidantsPatientsPermeabilityPhasePhase III Clinical TrialsPhenotypePlacebosPlasmaPlasma CellsPredictive ValueProtein CProteinsPulmonary InflammationRandomizedRecoveryReducing AgentsRegional PerfusionResearchRestSamplingSepsisSiteSubgroupSupportive careTestingTherapeutic EffectTubular formationUrineVascular EndotheliumVasoconstrictor Agentsantimicrobialascorbateclinical efficacycytokinedesignimprovedkidney dysfunctionmortalitynoveloxidationoxidative damagephase 3 studyphase III trialprecision medicineprospectiveresponseseptic patientssevere injurytargeted treatmenttreatment comparisontreatment effecttreatment groupurinaryventilation
项目摘要
Sepsis with acute organ dysfunction is a common condition with high morbidity and mortality and no specific
therapies other than antimicrobials. The NHLBI PETAL Network Phase 2B Acetaminophen and Ascorbate in
Sepsis: Targeted Therapy to Enhance Recovery (ASTER trial) is a randomized double blind platform trial that
will test the effect of two potential therapies, acetaminophen or vitamin C versus a common placebo to improve
lung, cardiovascular and kidney dysfunction in 900 patients with sepsis and pulmonary or cardiovascular
dysfunction including patients with sepsis due to COVID-19. The rationale for this clinical trial rests, in part, on
novel findings from our group and others that (1) circulating cell-free hemoglobin (CFH) is elevated in patients
with sepsis, including those with COVID-19; (2) higher plasma CFH in sepsis is associated with death and
organ dysfunction including ARDS and acute kidney injury; (3) both acetaminophen and vitamin C are
hemoprotein reductants that reduce the capacity of CFH to cause lipid peroxidation and other oxidant injury
and (4) acetaminophen and vitamin C can reduce the injurious effects of CFH on the microvascular
endothelium both in vitro and in the isolated perfused human lung. Although ASTER is well designed to test
the clinical efficacy of acetaminophen and vitamin C, key information will be needed to understand trial results
and plan for potential phase 3 studies. The proposed studies in this R01 will define the mechanisms by which
acetaminophen and vitamin C affect organ dysfunction in sepsis (Aim 1) and determine whether there are
subgroups that can be identified within the trial for whom a differential treatment effect exists (Aim 2). Specific
Aim 1 will determine the mechanisms by which acetaminophen and vitamin C improve lung and kidney
dysfunction in sepsis by testing the hypothesis that acetaminophen and vitamin C reduce levels of oxidized
ferryl (4+) hemoglobin resulting in decreased oxidative injury, inflammation, and endothelial injury as measured
by plasma, distal airspace fluid, and urinary biomarkers of hemoglobin oxidation (ferryl hemoglobin) lipid
peroxidation (F2-Isoprostanes, Isofurans), inflammation and endothelial injury. Distal airspace fluid will be
sampled at ten participating PETAL Network sites by collecting fluid that condenses on heat moisture
exchanger filters placed in the mechanical ventilator circuit, a method that has been developed and validated
by Dr. Ware's research group. Specific Aim 2 will identify whether previously described and validated
hyperinflammatory or hypoinflammatory subgroups of sepsis patients benefit more from treatment with
acetaminophen or vitamin C. A finding of heterogeneity of treatment effect in Aim 2 would be of great value for
predictive enrichment in a future phase 3 clinical trial. In summary, the proposed studies will greatly enhance
the value of the ASTER clinical trial by determining the biologic mechanisms of the therapeutic effects of
acetaminophen and Vitamin C and assessing for heterogeneity of treatment effect in this NHLBI-funded Phase
2B clinical trial.
脓毒症合并急性器官功能障碍是一种常见病,发病率和死亡率高,
除抗菌药物外的其他治疗方法。NHLBI PETAL网络2B期对乙酰氨基酚和抗坏血酸
脓毒症:靶向治疗以促进恢复(ASTER试验)是一项随机双盲平台试验,
将测试两种潜在疗法的效果,对乙酰氨基酚或维生素C与普通安慰剂,以改善
900例脓毒症和肺或心血管疾病患者的肺、心血管和肾功能障碍
包括因COVID-19导致败血症的患者。这项临床试验的基本原理部分取决于
我们小组和其他人的一项新发现是:(1)患者的循环无细胞血红蛋白(CFH)升高,
脓毒症患者,包括COVID-19患者;(2)脓毒症患者血浆CFH升高与死亡相关,
器官功能障碍,包括ARDS和急性肾损伤;(3)对乙酰氨基酚和维生素C都是
降低CFH引起脂质过氧化和其它氧化损伤能力的血红素蛋白还原剂
对乙酰氨基酚和维生素C可减轻CFH对微血管的损伤作用
内皮细胞在体外和在分离的灌注人肺。虽然ASTER的设计是为了测试
对乙酰氨基酚和维生素C的临床疗效,关键信息将需要了解试验结果
并计划潜在的3期研究。本R 01中拟定的研究将定义以下机制:
对乙酰氨基酚和维生素C影响脓毒症的器官功能障碍(目的1),并确定是否有
在试验中可以确定的存在差异治疗效应的亚组(目标2)。具体
目的1将确定对乙酰氨基酚和维生素C改善肺和肾功能的机制
通过检验对乙酰氨基酚和维生素C降低氧化应激水平的假设,
铁(4+)血红蛋白导致氧化损伤、炎症和内皮损伤减少,
通过血浆、远端气腔液体和血红蛋白氧化(铁血红蛋白)脂质的尿生物标志物
过氧化(F2-异前列腺素,异呋喃),炎症和内皮损伤。远端空气腔液体将
在10个参与PETAL网络的站点通过收集在热湿下冷凝的流体进行采样
在机械呼吸机回路中放置交换器过滤器,这是一种已经开发和验证的方法
威尔博士的研究小组具体目标2将确定先前描述和确认的
脓毒症患者的高炎症或低炎症亚组从以下治疗中获益更多:
醋氨酚或维生素C在目标2中发现治疗效果的异质性将具有重要价值,
在未来的3期临床试验中预测富集。总之,拟议的研究将大大提高
ASTER临床试验的价值,通过确定治疗效果的生物学机制,
对乙酰氨基酚和维生素C,并评估该NHLBI资助阶段的治疗效果异质性
2B临床试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lorraine B Ware其他文献
The role of red blood cells and cell-free hemoglobin in the pathogenesis of ARDS
- DOI:
10.1186/s40560-015-0086-3 - 发表时间:
2015-06-17 - 期刊:
- 影响因子:4.700
- 作者:
David R Janz;Lorraine B Ware - 通讯作者:
Lorraine B Ware
Can nicotine treat sepsis?
尼古丁可以治疗败血症吗?
- DOI:
10.1038/nm1104-1161 - 发表时间:
2004-11-01 - 期刊:
- 影响因子:50.000
- 作者:
Michael A Matthay;Lorraine B Ware - 通讯作者:
Lorraine B Ware
Lorraine B Ware的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lorraine B Ware', 18)}}的其他基金
The MUltidimenSional phenotyping In Critical care (MUSIC) Consortium: A pathway to precision medicine at the bedside
重症监护 (MUSIC) 多维度表型分析联盟:床边精准医疗的途径
- 批准号:
10649995 - 财政年份:2023
- 资助金额:
$ 42.68万 - 项目类别:
Mechanisms of organ dysfunction and recovery in the Acetaminophen and Ascorbate Trial in Sepsis
对乙酰氨基酚和抗坏血酸脓毒症试验中器官功能障碍和恢复的机制
- 批准号:
10502613 - 财政年份:2022
- 资助金额:
$ 42.68万 - 项目类别:
Peri-operative factors that drive cell-free hemoglobin-mediated primary graft dysfunction
驱动无细胞血红蛋白介导的原发性移植物功能障碍的围手术期因素
- 批准号:
10677593 - 财政年份:2022
- 资助金额:
$ 42.68万 - 项目类别:
Peri-operative factors that drive cell-free hemoglobin-mediated primary graft dysfunction
驱动无细胞血红蛋白介导的原发性移植物功能障碍的围手术期因素
- 批准号:
10431493 - 财政年份:2022
- 资助金额:
$ 42.68万 - 项目类别:
Haptoglobin 2 variant and endothelial glycocalyx shedding in sepsis-induced ARDS
脓毒症诱导的 ARDS 中结合珠蛋白 2 变异和内皮糖萼脱落
- 批准号:
10473750 - 财政年份:2021
- 资助金额:
$ 42.68万 - 项目类别:
Haptoglobin 2 variant and endothelial glycocalyx shedding in sepsis-induced ARDS
脓毒症诱导的 ARDS 中结合珠蛋白 2 变异和内皮糖萼脱落
- 批准号:
10277280 - 财政年份:2021
- 资助金额:
$ 42.68万 - 项目类别:
Haptoglobin 2 variant and endothelial glycocalyx shedding in sepsis-induced ARDS
脓毒症诱导的 ARDS 中结合珠蛋白 2 变异和内皮糖萼脱落
- 批准号:
10686129 - 财政年份:2021
- 资助金额:
$ 42.68万 - 项目类别:
The GOLD Study: Goal of Open Lung Ventilation in Donors
GOLD 研究:供体肺开放通气的目标
- 批准号:
9187048 - 财政年份:2014
- 资助金额:
$ 42.68万 - 项目类别:
Inflammatory and epithelial injury markers for ARDS prognosis:A validation study
ARDS 预后的炎症和上皮损伤标志物:一项验证研究
- 批准号:
8262086 - 财政年份:2012
- 资助金额:
$ 42.68万 - 项目类别:
Inflammatory and epithelial injury markers for ARDS prognosis:A validation study
ARDS 预后的炎症和上皮损伤标志物:一项验证研究
- 批准号:
8466368 - 财政年份:2012
- 资助金额:
$ 42.68万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 42.68万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 42.68万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 42.68万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 42.68万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 42.68万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 42.68万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 42.68万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 42.68万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 42.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 42.68万 - 项目类别:
Operating Grants